Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks ...

Aug 20, 2024 · Morgan Stanley analyst Tejas Savant maintained a Hold rating on Ginkgo Bioworks Holdings today and set a price target of $40.00. The company’s shares closed last …

CouponFollow Extension

$40.00
OFF

Analysts Offer Insights On Healthcare Companies: Ginkgo Bioworks ...

3 days from now

Aug 20, 2024 · Morgan Stanley analyst Tejas Savant maintained a Hold rating on Ginkgo Bioworks Holdings today and set a price target of $40.00. The company’s shares closed last …

businessinsider.com

$7.00
OFF

Analysts Offer Insights On Healthcare Companies: Ginkgo Bioworks ...

3 days from now

Aug 27, 2024 · BTIG analyst Mark Massaro maintained a Sell rating on Ginkgo Bioworks Holdings yesterday and set a price target of $7.00. The company’s shares closed last Monday at $7.88, …

businessinsider.com

$232
OFF

These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) …

3 days from now

Mar 6, 2024 · Following the latest downgrade, the seven analysts covering Ginkgo Bioworks Holdings provided consensus estimates of US$232m revenue in 2024, which would reflect a …

yahoo.com

$310
OFF

Here's What Analysts Are Forecasting For Ginkgo Bioworks …

3 days from now

Mar 30, 2022 · Taking into account the latest results, Ginkgo Bioworks Holdings' eight analysts currently expect revenues in 2022 to be US$310.3m, approximately in line with the last 12 …

yahoo.com

$1.10
OFF

Analysts Offer Insights On Healthcare Companies: Ginkgo Bioworks ...

3 days from now

Mar 5, 2024 · Goldman Sachs analyst Matthew Sykes assigned a Sell rating to Ginkgo Bioworks Holdings on February 29 and set a price target of $1.10. The company’s shares closed last …

businessinsider.com

$10.00
OFF

Analysts Offer Insights On Healthcare Companies: Bausch + Lomb ...

3 days from now

Oct 31, 2024 · Morgan Stanley analyst Tejas Savant maintained a Hold rating on Ginkgo Bioworks Holdings today and set a price target of $10.00. The company’s shares closed last …

businessinsider.com

FAQs about Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks ... Coupon?

What do analyst ratings mean for Ginkgo Bioworks holdings?

These ratings communicate expectations for the relative performance of Ginkgo Bioworks Holdings compared to the broader market. Price Targets: Analysts predict movements in price targets, offering estimates for Ginkgo Bioworks Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations. ...

Is Ginkgo Bioworks Holdings a good stock to buy?

The word on The Street in general, suggests a Hold analyst consensus rating for Ginkgo Bioworks Holdings with a $2.05 average price target. Barclays analyst Matt Miksic assigned a Sell rating to ZimVie Inc yesterday and set a price target of $16.00. ...

How do analysts perceive Ginkgo Bioworks holdings?

An in-depth analysis of recent analyst actions unveils how financial experts perceive Ginkgo Bioworks Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. ...

What does Ginkgo Bioworks holdings do?

Stay up to date on Ginkgo Bioworks Holdings analyst ratings. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. ...

How will Ginkgo Bioworks holdings perform in 2024?

Following the latest downgrade, the seven analysts covering Ginkgo Bioworks Holdings provided consensus estimates of US$232m revenue in 2024, which would reflect a discernible 7.8% decline on its sales over the past 12 months. Losses are predicted to fall substantially, shrinking 31% to US$0.31 per share. ...

Is Ginkgo Bioworks (DNA) a bad day?

The latest analyst coverage could presage a bad day for Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. ...